Soriatane is a drug used to treat
sever psoriasis in adults. It is manufactured by Roche Holding, AG, (Hoffman-La
Roche), and the generic name is Acitretin. It is a retinoid compound and is
similar to Accutane. Soriatane was launched in 1997.
Soriatane has been linked to
several dangerous side effects including serious birth defects, depression and suicidal thoughts.
Birth Defects: A pregnancy prevention program has been implemented
since the drug first came to the market. There are stringent guidelines in
place that must be followed before a doctor can prescribe the drug to a woman.
They must present two negative pregnancy tests, use two or more birth control
methods one month prior to treatment, and they must continue their birth
control treatment for three years after discontinuing use of the drug. Women
must also sign an informed consent agreement before treatment.
Depression/Suicide: In May
2003, Roche added a warning to Soriatane’s label, alerting the public of
the drug’s link to depression, aggression and thoughts of self-harm. Similar to
Accutane, common Soriatane side
effects include depression, aggressive feelings, mood swings, suicidal
ideation, and self-harm.
Other Side Effects: Increased intracranial pressure, alteration in
lipid levels, eye problems, cardiovascular effects, bone spurs, and pancreatitis.
There has not been an MDL formed to consolidate Soriatane lawsuits. There are too few cases to merit an MDL at this time.
Pittman, Dutton & Hellums, P.C., is not currently pursuing lawsuits for this drug, but we will continue to monitor any new FDA warning label changes which could affect the legal landscape.
